About this Research Topic
Most patients with locally advanced breast cancer undergo pre-surgery treatment known as neoadjuvant chemotherapy (NAC) to reduce the tumor’s size and improve surgical outcomes, cosmetic results, and chances of conservative management, as well as to control tumor progression and observe tumor sensitivity (or resistance) to the chosen treatment regimen. Studies have documented better survival outcomes in patients achieving a complete pathological remission than patients who have residual or progressive disease at the time of definitive surgery. The mechanisms of primary resistance and strategies to overcome those are a matter of intense research.
In this Research Topic, we will focus on studies that tackle the most recent advances in diagnosing and treating breast cancer using neoadjuvant systemic therapy. The focus is on new biomarkers and targeted therapies, including immunotherapy. Apart from tumor molecular characteristics, we will also cover the patient’s genetics and metabolism.
This collection will include Original Research papers and Review Articles.
Manuscripts should focus on:
- The clinical effects of neoadjuvant therapy on different breast cancer intrinsic subtypes; new treatment options
- Post-neoadjuvant treatment strategies for patients with residual or progressive disease
- Molecular characterization of primary and residual tumors
- Neoadjuvant chemotherapy in patients with underlying genetic abnormalities or metabolic dysfunction
- New neoadjuvant treatment strategies
- Advances in neoadjuvant clinical trial’s design
Keywords: Breast cancer, Neoadjuvant Chemotherapy, Luminal subtypes, HER-2, biomarkers, Post-neoadjuvant, Primary resistance
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.